BridgeBio Pharma's Total Assets for the quarter that ended in Sep. 2024 was $665.0 Mil.
During the past 12 months, BridgeBio Pharma's average Total Assets Growth Rate was 256.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 4.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 29.60% per year.
During the past 7 years, BridgeBio Pharma's highest 3-Year average Total Assets Growth Rate was 151.70%. The lowest was 4.90%. And the median was 51.80%.
The historical data trend for BridgeBio Pharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
BridgeBio Pharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (NAS:BBIO) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
BridgeBio Pharma's Asset Turnover for the quarter that ended in Sep. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
BridgeBio Pharma Total Assets Related Terms
Thank you for viewing the detailed overview of BridgeBio Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BBIO has been successfully added to your 